Skip to Content

Posts tagged with "Why Everyone Loves Us"

  • Cardiovascular Disease

    Steve Nissen vs. GlaxoSmithKline

    You don’t often get to see so direct an exchange of blows as this: Steve Nissen, of cardiology and drug-safety fame, published an editorial about GlaxoSmithKline and Avandia (rosiglitazone) earlier this year in the European Heart Journal. And GSK took exception to it – enough so that that the company’s head of R&D, Moncef Sla… Read More
  • Business and Markets

    A Tiny Little Presentation Tip

    Protip: making slides that refer to your company’s drug as “snake oil” and illustrate its use with a cartoon of witches standing around a cauldron is perhaps unwise. Particularly when you’re in Marketing. Particularly when you also include unapproved uses for your drug on the slides. Worth noting, Pfizer. Read More
  • Business and Markets

    Colchicine’s Price Goes Through the Roof

    We all hear about the new drugs that have just been approved, and we all keep track of the drugs that are coming off patent. But what about the really old ones, the drugs that made it to the market long before today’s regulatory framework? There have long been medicines that are generally recognized as… Read More
  • Alzheimer's Disease

    Two Doses of Crazy

    I’d like to take the time this morning to deal with two conspiracy theorists, and I’ll take them in order of increasing foil-hat thickness. First up is Joe Collier, an emeritus professor who writes a blog for the British Medical Journal. He notes the recent study that suggested that cell phone emissions could have a… Read More
  • Business and Markets

    Selling It, And Selling It Hard

    There’s a long, detailed article up over at Bloomberg on the recent run of huge fines for off-label promotion of drugs. Pfizer, Lilly, Bristol-Meyers Squibb, and Schering-Plough all get mentioned in great detail. And there’s a key point from the whole depressing thing: the reason that marketing departments do this kind of thing is that… Read More
  • Drug Industry History

    Fall From Grace

    A couple of articles have come together and gotten me to thinking. Back during the summer, long-time medicinal chemist Mark Murcko published a short editorial in Drug Discovery Today comemmerating the Apollo 11 moon landing’s 40th anniversary: “People like me, who are old enough to actually remember the events of July 1969, are instantl… Read More
  • Business and Markets

    Lexapro, Forest Labs, and the Hard Sell

    Forest Labs has done very, very well with Lexapro (escitalopram) over the years. They’re a comparatively small company, and their collaboration with Lundbeck (also a comparatively small company) in the antidepressant field has been the biggest event in their history. Lexapro is the pure enantiomer of the earlier Lundbeck drug Celexa (citalopr… Read More
  • Drug Development

    Spray-Painted For Success

    I do a lot of talking around here about how the general public doesn’t really have a good idea of what goes on inside a drug company. But a conversation with a colleague has put me to thinking that this might be largely our own fault. Consider the public face that our industry projects. Look… Read More
  • Animal Testing

    Animal Rights, You Say?

    Novartis has had trouble for years with animal rights activists, and now things are getting nastier than ever: Novartis CEO Daniel Vasella says the people who burned down his holiday home and defiled his family’s graves are not criminals but “terrorists” beyond dialogue. In an interview with the SonntagsBlick newspaper, the 55-yea… Read More
  • Business and Markets


    As much as I defend the industry I work in, I have to talk about things that we do that I don’t think are so defensible. Another one of those has come up thanks to the New York Times and PLoS Medicine, who obtained a pile of records from a current court case. This article… Read More